nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—EGFR—adrenal gland cancer	0.228	0.767	CbGaD
Erlotinib—pancreatic cancer—adrenal gland cancer	0.228	0.378	CtDrD
Erlotinib—kidney cancer—adrenal gland cancer	0.191	0.317	CtDrD
Erlotinib—lung cancer—adrenal gland cancer	0.184	0.305	CtDrD
Erlotinib—ABCB1—adrenal gland cancer	0.0695	0.233	CbGaD
Erlotinib—STK10—renal vein—adrenal gland cancer	0.0101	0.224	CbGeAlD
Erlotinib—STK10—renal artery—adrenal gland cancer	0.00682	0.15	CbGeAlD
Erlotinib—UGT1A1—urine—adrenal gland cancer	0.00181	0.0399	CbGeAlD
Erlotinib—HIPK4—gonad—adrenal gland cancer	0.00101	0.0222	CbGeAlD
Erlotinib—Vandetanib—EGFR—adrenal gland cancer	0.000921	0.447	CrCbGaD
Erlotinib—Gefitinib—EGFR—adrenal gland cancer	0.000875	0.424	CrCbGaD
Erlotinib—AURKC—gonad—adrenal gland cancer	0.000859	0.019	CbGeAlD
Erlotinib—CYP1A2—urine—adrenal gland cancer	0.000799	0.0176	CbGeAlD
Erlotinib—EPHA6—gonad—adrenal gland cancer	0.000796	0.0176	CbGeAlD
Erlotinib—AURKC—adrenal gland—adrenal gland cancer	0.000749	0.0165	CbGeAlD
Erlotinib—TNK1—pituitary gland—adrenal gland cancer	0.000713	0.0157	CbGeAlD
Erlotinib—JAK3—adrenal gland—adrenal gland cancer	0.000693	0.0153	CbGeAlD
Erlotinib—PIP4K2C—adrenal cortex—adrenal gland cancer	0.000684	0.0151	CbGeAlD
Erlotinib—ULK3—adrenal cortex—adrenal gland cancer	0.000654	0.0144	CbGeAlD
Erlotinib—TNK1—adrenal gland—adrenal gland cancer	0.000637	0.0141	CbGeAlD
Erlotinib—FLT3—gonad—adrenal gland cancer	0.000628	0.0139	CbGeAlD
Erlotinib—MKNK1—adrenal cortex—adrenal gland cancer	0.000615	0.0136	CbGeAlD
Erlotinib—ABL2—pituitary gland—adrenal gland cancer	0.000585	0.0129	CbGeAlD
Erlotinib—SLK—adrenal cortex—adrenal gland cancer	0.000583	0.0129	CbGeAlD
Erlotinib—CYP3A4—urine—adrenal gland cancer	0.000579	0.0128	CbGeAlD
Erlotinib—CYP2D6—urine—adrenal gland cancer	0.000569	0.0126	CbGeAlD
Erlotinib—PIP4K2C—gonad—adrenal gland cancer	0.000567	0.0125	CbGeAlD
Erlotinib—PIP4K2C—cardiac atrium—adrenal gland cancer	0.000566	0.0125	CbGeAlD
Erlotinib—PIP4K2C—pituitary gland—adrenal gland cancer	0.000553	0.0122	CbGeAlD
Erlotinib—FLT3—adrenal gland—adrenal gland cancer	0.000547	0.0121	CbGeAlD
Erlotinib—ULK3—gonad—adrenal gland cancer	0.000541	0.0119	CbGeAlD
Erlotinib—ULK3—cardiac atrium—adrenal gland cancer	0.000541	0.0119	CbGeAlD
Erlotinib—ULK3—pituitary gland—adrenal gland cancer	0.000528	0.0117	CbGeAlD
Erlotinib—ABL2—adrenal gland—adrenal gland cancer	0.000522	0.0115	CbGeAlD
Erlotinib—EGFR—adrenal gland—adrenal gland cancer	0.00051	0.0112	CbGeAlD
Erlotinib—MKNK1—gonad—adrenal gland cancer	0.000509	0.0112	CbGeAlD
Erlotinib—MKNK1—cardiac atrium—adrenal gland cancer	0.000509	0.0112	CbGeAlD
Erlotinib—MKNK1—pituitary gland—adrenal gland cancer	0.000497	0.011	CbGeAlD
Erlotinib—PIP4K2C—adrenal gland—adrenal gland cancer	0.000494	0.0109	CbGeAlD
Erlotinib—SLK—cardiac atrium—adrenal gland cancer	0.000482	0.0106	CbGeAlD
Erlotinib—ULK3—adrenal gland—adrenal gland cancer	0.000472	0.0104	CbGeAlD
Erlotinib—SLK—pituitary gland—adrenal gland cancer	0.000471	0.0104	CbGeAlD
Erlotinib—MAP2K5—adrenal cortex—adrenal gland cancer	0.000452	0.00998	CbGeAlD
Erlotinib—MKNK1—adrenal gland—adrenal gland cancer	0.000444	0.0098	CbGeAlD
Erlotinib—SLK—adrenal gland—adrenal gland cancer	0.00042	0.00928	CbGeAlD
Erlotinib—STK10—gonad—adrenal gland cancer	0.00042	0.00926	CbGeAlD
Erlotinib—MAP2K5—cardiac atrium—adrenal gland cancer	0.000374	0.00826	CbGeAlD
Erlotinib—STK10—adrenal gland—adrenal gland cancer	0.000366	0.00807	CbGeAlD
Erlotinib—MAP2K5—pituitary gland—adrenal gland cancer	0.000366	0.00807	CbGeAlD
Erlotinib—ABL1—adrenal cortex—adrenal gland cancer	0.000349	0.0077	CbGeAlD
Erlotinib—MAP2K5—adrenal gland—adrenal gland cancer	0.000327	0.00721	CbGeAlD
Erlotinib—ABL1—gonad—adrenal gland cancer	0.000289	0.00638	CbGeAlD
Erlotinib—ABL1—cardiac atrium—adrenal gland cancer	0.000289	0.00637	CbGeAlD
Erlotinib—ABL1—pituitary gland—adrenal gland cancer	0.000282	0.00622	CbGeAlD
Erlotinib—Gefitinib—ABCB1—adrenal gland cancer	0.000266	0.129	CrCbGaD
Erlotinib—SLCO2B1—adrenal gland—adrenal gland cancer	0.000254	0.00561	CbGeAlD
Erlotinib—ABL1—adrenal gland—adrenal gland cancer	0.000252	0.00556	CbGeAlD
Erlotinib—CYP1B1—gonad—adrenal gland cancer	0.000245	0.0054	CbGeAlD
Erlotinib—CYP1B1—pituitary gland—adrenal gland cancer	0.000239	0.00527	CbGeAlD
Erlotinib—ALB—adrenal gland—adrenal gland cancer	0.000232	0.00513	CbGeAlD
Erlotinib—ABCG2—adrenal cortex—adrenal gland cancer	0.00022	0.00486	CbGeAlD
Erlotinib—CYP1B1—adrenal gland—adrenal gland cancer	0.000213	0.00471	CbGeAlD
Erlotinib—CYP2C8—pituitary gland—adrenal gland cancer	0.000183	0.00404	CbGeAlD
Erlotinib—ABCG2—pituitary gland—adrenal gland cancer	0.000178	0.00392	CbGeAlD
Erlotinib—CYP1A1—cardiac atrium—adrenal gland cancer	0.000173	0.00381	CbGeAlD
Erlotinib—ABCG2—adrenal gland—adrenal gland cancer	0.000159	0.00351	CbGeAlD
Erlotinib—ABCB1—adrenal cortex—adrenal gland cancer	0.000109	0.00239	CbGeAlD
Erlotinib—ABCB1—gonad—adrenal gland cancer	8.99e-05	0.00198	CbGeAlD
Erlotinib—ABCB1—pituitary gland—adrenal gland cancer	8.77e-05	0.00194	CbGeAlD
Erlotinib—ABCB1—adrenal gland—adrenal gland cancer	7.83e-05	0.00173	CbGeAlD
Erlotinib—EGFR—Signaling by NGF—BRAF—adrenal gland cancer	1.98e-05	0.000384	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	1.97e-05	0.000383	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—adrenal gland cancer	1.97e-05	0.000382	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—adrenal gland cancer	1.97e-05	0.000382	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IGF2—adrenal gland cancer	1.95e-05	0.000379	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—GNAS—adrenal gland cancer	1.94e-05	0.000376	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—adrenal gland cancer	1.93e-05	0.000375	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MEN1—adrenal gland cancer	1.92e-05	0.000373	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SH3KBP1—adrenal gland cancer	1.91e-05	0.000371	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SDHD—adrenal gland cancer	1.91e-05	0.00037	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—RRM1—adrenal gland cancer	1.91e-05	0.00037	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—POMC—adrenal gland cancer	1.9e-05	0.000369	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IGF1R—adrenal gland cancer	1.89e-05	0.000366	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	1.88e-05	0.000365	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TSHR—adrenal gland cancer	1.86e-05	0.000361	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—adrenal gland cancer	1.86e-05	0.00036	CbGpPWpGaD
Erlotinib—MKNK1—Disease—BRAF—adrenal gland cancer	1.84e-05	0.000357	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	1.83e-05	0.000356	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—POMC—adrenal gland cancer	1.83e-05	0.000356	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	1.83e-05	0.000355	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PRKACA—adrenal gland cancer	1.8e-05	0.00035	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SDHB—adrenal gland cancer	1.8e-05	0.000349	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ZNRF3—adrenal gland cancer	1.8e-05	0.000349	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SDHD—adrenal gland cancer	1.78e-05	0.000345	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—RRM1—adrenal gland cancer	1.78e-05	0.000345	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CDC42—adrenal gland cancer	1.78e-05	0.000344	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—adrenal gland cancer	1.77e-05	0.000343	CbGpPWpGaD
Erlotinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	1.76e-05	0.000342	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—POMC—adrenal gland cancer	1.74e-05	0.000338	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CDC42—adrenal gland cancer	1.71e-05	0.000331	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SDHB—adrenal gland cancer	1.7e-05	0.00033	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—adrenal gland cancer	1.68e-05	0.000327	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	1.68e-05	0.000326	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	1.67e-05	0.000324	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—POMC—adrenal gland cancer	1.66e-05	0.000323	CbGpPWpGaD
Erlotinib—JAK3—Immune System—BAD—adrenal gland cancer	1.65e-05	0.00032	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TERT—adrenal gland cancer	1.63e-05	0.000315	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—RRM1—adrenal gland cancer	1.62e-05	0.000314	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SDHD—adrenal gland cancer	1.62e-05	0.000314	CbGpPWpGaD
Erlotinib—EGFR—Disease—SPRY2—adrenal gland cancer	1.61e-05	0.000312	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SPARC—adrenal gland cancer	1.59e-05	0.000308	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—adrenal gland cancer	1.59e-05	0.000307	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SDHB—adrenal gland cancer	1.56e-05	0.000302	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SDHB—adrenal gland cancer	1.55e-05	0.000301	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	1.54e-05	0.000298	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CDC42—adrenal gland cancer	1.53e-05	0.000297	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	1.52e-05	0.000295	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—adrenal gland cancer	1.51e-05	0.000294	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	1.49e-05	0.00029	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTGS2—adrenal gland cancer	1.49e-05	0.000288	CbGpPWpGaD
Erlotinib—EGFR—Disease—MEN1—adrenal gland cancer	1.47e-05	0.000286	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF2—adrenal gland cancer	1.47e-05	0.000286	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PRKACA—adrenal gland cancer	1.47e-05	0.000285	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—GNAS—adrenal gland cancer	1.46e-05	0.000283	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—adrenal gland cancer	1.46e-05	0.000282	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—BAD—adrenal gland cancer	1.45e-05	0.000281	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	1.43e-05	0.000278	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PRKACA—adrenal gland cancer	1.43e-05	0.000277	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF1R—adrenal gland cancer	1.42e-05	0.000276	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MED12—adrenal gland cancer	1.42e-05	0.000276	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—BAD—adrenal gland cancer	1.41e-05	0.000274	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—adrenal gland cancer	1.38e-05	0.000267	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SDHB—adrenal gland cancer	1.36e-05	0.000263	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PRKACA—adrenal gland cancer	1.34e-05	0.00026	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	1.34e-05	0.00026	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PRKACA—adrenal gland cancer	1.33e-05	0.000259	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CTNNB1—adrenal gland cancer	1.33e-05	0.000258	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MED12—adrenal gland cancer	1.33e-05	0.000257	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	1.31e-05	0.000255	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—POMC—adrenal gland cancer	1.3e-05	0.000253	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—BRAF—adrenal gland cancer	1.29e-05	0.00025	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SDHB—adrenal gland cancer	1.28e-05	0.000248	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDC42—adrenal gland cancer	1.25e-05	0.000242	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—BAD—adrenal gland cancer	1.24e-05	0.00024	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GNRH1—adrenal gland cancer	1.23e-05	0.000239	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	1.23e-05	0.000238	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TERT—adrenal gland cancer	1.23e-05	0.000238	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	1.22e-05	0.000237	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PRKACA—adrenal gland cancer	1.22e-05	0.000237	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	1.21e-05	0.000235	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDC42—adrenal gland cancer	1.21e-05	0.000235	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MED12—adrenal gland cancer	1.21e-05	0.000234	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF2—adrenal gland cancer	1.2e-05	0.000233	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—adrenal gland cancer	1.2e-05	0.000233	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—GNAS—adrenal gland cancer	1.19e-05	0.000231	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—BAD—adrenal gland cancer	1.19e-05	0.000231	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	1.19e-05	0.00023	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	1.17e-05	0.000227	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF1R—adrenal gland cancer	1.16e-05	0.000225	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	1.16e-05	0.000225	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SDHD—adrenal gland cancer	1.16e-05	0.000225	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—RRM1—adrenal gland cancer	1.16e-05	0.000225	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—CDC42—adrenal gland cancer	1.14e-05	0.00022	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CDC42—adrenal gland cancer	1.13e-05	0.00022	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SPRY2—adrenal gland cancer	1.13e-05	0.000219	CbGpPWpGaD
Erlotinib—EGFR—Disease—PRKACA—adrenal gland cancer	1.13e-05	0.000218	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—adrenal gland cancer	1.11e-05	0.000216	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TSHR—adrenal gland cancer	1.1e-05	0.000213	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—RRM1—adrenal gland cancer	1.1e-05	0.000212	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SDHD—adrenal gland cancer	1.1e-05	0.000212	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IGF2—adrenal gland cancer	1.1e-05	0.000212	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—GNAS—adrenal gland cancer	1.09e-05	0.000211	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CTNNB1—adrenal gland cancer	1.09e-05	0.000211	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SDHB—adrenal gland cancer	1.08e-05	0.00021	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—GNAS—adrenal gland cancer	1.08e-05	0.00021	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—CTNNB1—adrenal gland cancer	1.08e-05	0.00021	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—BAD—adrenal gland cancer	1.07e-05	0.000207	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—adrenal gland cancer	1.05e-05	0.000204	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PRKACA—adrenal gland cancer	1.04e-05	0.000201	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDC42—adrenal gland cancer	1.03e-05	0.000201	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MEN1—adrenal gland cancer	1.03e-05	0.0002	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	1.02e-05	0.000197	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—RRM1—adrenal gland cancer	1e-05	0.000195	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SDHD—adrenal gland cancer	1e-05	0.000195	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TERT—adrenal gland cancer	1e-05	0.000194	CbGpPWpGaD
Erlotinib—ALB—Metabolism—RRM1—adrenal gland cancer	9.99e-06	0.000194	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SDHD—adrenal gland cancer	9.99e-06	0.000194	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—adrenal gland cancer	9.97e-06	0.000193	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—POMC—adrenal gland cancer	9.84e-06	0.000191	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—BRAF—adrenal gland cancer	9.71e-06	0.000188	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PRKACA—adrenal gland cancer	9.68e-06	0.000188	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDC42—adrenal gland cancer	9.55e-06	0.000185	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CTNNB1—adrenal gland cancer	9.54e-06	0.000185	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	9.46e-06	0.000183	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—adrenal gland cancer	9.41e-06	0.000183	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	9.4e-06	0.000182	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	9.36e-06	0.000181	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CTNNB1—adrenal gland cancer	9.31e-06	0.000181	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CTNNB1—adrenal gland cancer	9.23e-06	0.000179	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	9.22e-06	0.000179	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PRKACA—adrenal gland cancer	8.8e-06	0.000171	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SDHD—adrenal gland cancer	8.75e-06	0.00017	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RRM1—adrenal gland cancer	8.75e-06	0.00017	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BAD—adrenal gland cancer	8.7e-06	0.000169	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MED12—adrenal gland cancer	8.65e-06	0.000168	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—adrenal gland cancer	8.6e-06	0.000167	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—adrenal gland cancer	8.56e-06	0.000166	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	8.53e-06	0.000165	CbGpPWpGaD
Erlotinib—ABL1—Immune System—BAD—adrenal gland cancer	8.45e-06	0.000164	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GNAS—adrenal gland cancer	8.41e-06	0.000163	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SDHB—adrenal gland cancer	8.37e-06	0.000162	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ABCB1—adrenal gland cancer	8.25e-06	0.00016	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RRM1—adrenal gland cancer	8.25e-06	0.00016	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SDHD—adrenal gland cancer	8.25e-06	0.00016	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	8.24e-06	0.00016	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MED12—adrenal gland cancer	8.17e-06	0.000158	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CTNNB1—adrenal gland cancer	8.15e-06	0.000158	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—POMC—adrenal gland cancer	8.02e-06	0.000156	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BRAF—adrenal gland cancer	7.92e-06	0.000154	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—adrenal gland cancer	7.9e-06	0.000153	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PRKACA—adrenal gland cancer	7.88e-06	0.000153	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GNAS—adrenal gland cancer	7.84e-06	0.000152	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ABCB1—adrenal gland cancer	7.69e-06	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Disease—TERT—adrenal gland cancer	7.66e-06	0.000149	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—adrenal gland cancer	7.56e-06	0.000147	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MED12—adrenal gland cancer	7.49e-06	0.000145	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MED12—adrenal gland cancer	7.45e-06	0.000144	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—adrenal gland cancer	7.37e-06	0.000143	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	7.3e-06	0.000142	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—POMC—adrenal gland cancer	7.28e-06	0.000141	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BAD—adrenal gland cancer	7.22e-06	0.00014	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GNAS—adrenal gland cancer	7.13e-06	0.000138	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—adrenal gland cancer	7.05e-06	0.000137	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CTNNB1—adrenal gland cancer	7.02e-06	0.000136	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ABCB1—adrenal gland cancer	7e-06	0.000136	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RRM1—adrenal gland cancer	6.98e-06	0.000135	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SDHD—adrenal gland cancer	6.98e-06	0.000135	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	6.69e-06	0.00013	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDC42—adrenal gland cancer	6.69e-06	0.00013	CbGpPWpGaD
Erlotinib—EGFR—Disease—BAD—adrenal gland cancer	6.66e-06	0.000129	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	6.66e-06	0.000129	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—adrenal gland cancer	6.63e-06	0.000129	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MED12—adrenal gland cancer	6.52e-06	0.000127	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF2—adrenal gland cancer	6.45e-06	0.000125	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GNAS—adrenal gland cancer	6.39e-06	0.000124	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PRKACA—adrenal gland cancer	6.31e-06	0.000122	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1R—adrenal gland cancer	6.23e-06	0.000121	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—adrenal gland cancer	6.19e-06	0.00012	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MED12—adrenal gland cancer	6.15e-06	0.000119	CbGpPWpGaD
Erlotinib—EGFR—Disease—BRAF—adrenal gland cancer	6.07e-06	0.000118	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PRKACA—adrenal gland cancer	5.96e-06	0.000116	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.82e-06	0.000113	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—adrenal gland cancer	5.72e-06	0.000111	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—POMC—adrenal gland cancer	5.66e-06	0.00011	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—adrenal gland cancer	5.56e-06	0.000108	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—adrenal gland cancer	5.56e-06	0.000108	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PRKACA—adrenal gland cancer	5.46e-06	0.000106	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PRKACA—adrenal gland cancer	5.43e-06	0.000105	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	5.39e-06	0.000105	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	5.39e-06	0.000105	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—adrenal gland cancer	5.36e-06	0.000104	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.34e-06	0.000104	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.31e-06	0.000103	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—POMC—adrenal gland cancer	5.28e-06	0.000102	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MED12—adrenal gland cancer	5.21e-06	0.000101	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GNAS—adrenal gland cancer	5.11e-06	9.91e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—adrenal gland cancer	5.02e-06	9.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—adrenal gland cancer	4.9e-06	9.51e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GNAS—adrenal gland cancer	4.83e-06	9.37e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—POMC—adrenal gland cancer	4.8e-06	9.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PRKACA—adrenal gland cancer	4.76e-06	9.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—adrenal gland cancer	4.75e-06	9.21e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—adrenal gland cancer	4.74e-06	9.19e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—adrenal gland cancer	4.67e-06	9.06e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BAD—adrenal gland cancer	4.67e-06	9.05e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	4.66e-06	9.03e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—adrenal gland cancer	4.53e-06	8.79e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—adrenal gland cancer	4.52e-06	8.76e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	4.48e-06	8.7e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GNAS—adrenal gland cancer	4.43e-06	8.59e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—adrenal gland cancer	4.4e-06	8.54e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GNAS—adrenal gland cancer	4.4e-06	8.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—adrenal gland cancer	4.38e-06	8.51e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—adrenal gland cancer	4.34e-06	8.43e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—adrenal gland cancer	4.32e-06	8.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—POMC—adrenal gland cancer	4.3e-06	8.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—adrenal gland cancer	4.25e-06	8.24e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—adrenal gland cancer	4.21e-06	8.17e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MED12—adrenal gland cancer	4.02e-06	7.8e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNAS—adrenal gland cancer	3.86e-06	7.48e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—adrenal gland cancer	3.83e-06	7.43e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—adrenal gland cancer	3.81e-06	7.38e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	3.8e-06	7.37e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	3.71e-06	7.2e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNAS—adrenal gland cancer	3.63e-06	7.05e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	3.57e-06	6.92e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—adrenal gland cancer	3.47e-06	6.73e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—POMC—adrenal gland cancer	3.44e-06	6.68e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—POMC—adrenal gland cancer	3.25e-06	6.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNAS—adrenal gland cancer	3.08e-06	5.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—adrenal gland cancer	3.07e-06	5.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	3.02e-06	5.86e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—POMC—adrenal gland cancer	2.98e-06	5.78e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—POMC—adrenal gland cancer	2.96e-06	5.75e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	2.93e-06	5.69e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—adrenal gland cancer	2.75e-06	5.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—POMC—adrenal gland cancer	2.6e-06	5.04e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—adrenal gland cancer	2.59e-06	5.03e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—POMC—adrenal gland cancer	2.45e-06	4.75e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—adrenal gland cancer	2.38e-06	4.61e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	2.38e-06	4.61e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—adrenal gland cancer	2.36e-06	4.59e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	2.33e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—POMC—adrenal gland cancer	2.07e-06	4.02e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—adrenal gland cancer	2.07e-06	4.02e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—adrenal gland cancer	2.04e-06	3.96e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	1.95e-06	3.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	1.65e-06	3.21e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—POMC—adrenal gland cancer	1.6e-06	3.1e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	1.28e-06	2.48e-05	CbGpPWpGaD
